Aromatic Readthrough Compounds to Reduce Aminoglycoside Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for genetic disorders caused by premature termination codons, such as cystic fibrosis and Duchenne muscular dystrophy, are limited by the need for more effective compounds to enhance readthrough of these codons, as existing therapies like aminoglycosides and Ataluren have limitations in efficacy and side effects.
Innovation Solution
Development of novel aromatic compounds and pharmaceutical compositions that include these compounds, which can enhance readthrough of premature termination codons when administered with aminoglycosides or eRF3 modulators, potentially increasing readthrough by over 100% compared to aminoglycosides alone.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If aminoglycosides are used to facilitate readthrough of premature stop codons, then readthrough activity is improved, but side effects and toxicity increase
Solution Approach 1:
The patent introduces non-aminoglycoside compounds (such as ataluren and other readthrough modulators) as intermediary substances that can facilitate stop codon readthrough without the severe toxic effects of aminoglycosides. These compounds act as mediators between the ribosome and the stop codon, enabling readthrough through a different mechanism that avoids the harmful interactions caused by aminoglycosides.
Solution Approach 2:
The patent changes the chemical parameters and structural characteristics of readthrough-inducing compounds by moving from aminoglycoside structures to entirely different chemical classes (such as aryl-guanidino compounds like ataluren). This parameter change allows achievement of readthrough activity while eliminating the toxic properties associated with the aminoglycoside chemical structure.
2Productivity
If higher doses of aminoglycosides are administered to enhance readthrough, then readthrough efficacy is improved, but toxicity and side effects worsen
Solution Approach 1:
The patent employs readthrough modulators that can be administered at lower effective doses compared to aminoglycosides, achieving comparable or superior readthrough efficacy without the dose-dependent toxicity of aminoglycosides. These compounds represent a more favorable dosage profile where lower amounts are required to achieve therapeutic effect.
Solution Approach 2:
The patent uses alternative readthrough modulators as intermediary substances that can achieve readthrough at lower concentrations than aminoglycosides. These mediators interact with the translation machinery through different mechanisms that are less toxic, allowing effective treatment at lower doses.
3Reliability
If existing readthrough compounds are used, then therapeutic benefit is achieved, but efficacy is limited compared to potential of novel compounds
Solution Approach 1:
The patent changes the chemical and structural parameters of readthrough compounds by developing novel aromatic compounds with specific molecular features (such as aryl-guanidino structures). These parameter changes in molecular structure lead to improved pharmacological properties including enhanced readthrough efficacy, better bioavailability, and reduced toxicity compared to existing compounds.
Solution Approach 2:
The patent creates composite pharmaceutical compositions that combine multiple readthrough-modulating compounds (such as combining ataluren with aminoglycosides or other modulators). This composite approach synergistically enhances readthrough efficacy beyond what single compounds can achieve, while potentially reducing individual compound dosages and associated toxicities.
Data Source
AI summary
Disclosed herein are new aromatic compounds, compositions that include one or more aromatic compounds, and methods of synthesizing the same. Also disclosed herein are methods of enhancing readthrough of genes containing premature termination codons with one or more compounds or compositions described herein.